EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity

Affiliations

• ¹ Division of Hematology, Medical University of Graz, Graz, Austria.
• ² Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
• ³ CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
• ⁴ 5th Medical Department with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Vienna, Austria.
• ⁵ Sigmund Freud University, Vienna, Austria.
• ⁶ Gottfried Schatz Research Center for Cell Signaling, Metabolism & Aging, Medical University of Graz, Graz, Austria.
• ⁷ Division of Cell Biology, Histology and Embryology, Medical University of Graz, Graz, Austria.
• ⁸ BioTechMed-Graz, Graz, Austria.
• ⁹ University Hospital Heidelberg, Heidelberg, Germany.
• ¹⁰ Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
• ¹¹ Division of Hematology, Medical University of Graz, Graz, Austria. vc390@mrc-cu.cam.ac.uk.
• ¹² MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, United Kingdom. vc390@mrc-cu.cam.ac.uk.
• ¹³ Division of Hematology, Medical University of Graz, Graz, Austria. armin.zebisch@medunigraz.at.
• ¹⁴ Otto-Loewi Research Center for Vascular Biology, Immunology and Inflammation, Division of Pharmacology, Medical University of Graz, Graz, Austria. armin.zebisch@medunigraz.at.